NCT01584843View on ClinicalTrials.gov

Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

June 30, 2014

Conditions
Strabismus
Interventions
DRUG

GSK1358820

IM injection of Botulinum Toxin Type A

Trial Locations (13)

494-0001

GSK Investigational Site, Aichi

812-0011

GSK Investigational Site, Fukuoka

663-8501

GSK Investigational Site, Hyōgo

890-0046

GSK Investigational Site, Kagoshima

252-0375

GSK Investigational Site, Kanagawa

880-0035

GSK Investigational Site, Miyazaki

885-0051

GSK Investigational Site, Miyazaki

535-0021

GSK Investigational Site, Osaka

569-8686

GSK Investigational Site, Osaka

431-3192

GSK Investigational Site, Shizuoka

101-0062

GSK Investigational Site, Tokyo

134-0088

GSK Investigational Site, Tokyo

750-0061

GSK Investigational Site, Yamaguchi

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01584843 - Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus | Biotech Hunter | Biotech Hunter